Associate Director, Clinical Operations in Cell Therapy (CAR-T) for Immix Bio. Immix Biopharma, Inc. (“ImmixBio”) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering personalized immunotherapies for cancer and rare diseases. Our subsidiary Nexcella, Inc.’s lead cell therapy product, NXC-201, is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory AL Amyloidosis and Multiple Myeloma.

Clinical development of autologous engineered T cell (CAART) products that target B cell-mediated autoimmune diseases. Lead the phase 1 program for MuSK-CAART in MuSK-associated myasthenia gravis (MG).

Clinical development of a portfolio of small molecule TLR 7/8 agonist, including Phase I/II dose escalation and dose expansion studies (BDB001).

Clinical development of the TLR 7/8 agonist portfolio in the US and Europe, including Phase II program for BDB001 monotherapy in anti-PD-(L)1 refractory tumors.

Sr. Study Manager in a hybrid Study Manager / Clinical Scientist role in a multi- study international trial program for Bridion (sugammadex), in Anesthesia & Critical Care. I was responsible for study operations and vendor management related to NMTM (Neuromuscular Transmission Monitoring) data collection, monitoring and interpretation. NMTM data are a surrogate marker for efficacy and safety in studies of neuromuscular blockade and reversal.

Sr. Study Manager Tasks and responsibilities: Operational planning, feasibility, and execution of clinical protocols.Accomplishments: lead the program team through early study planning, development and startup execution activities; transitioned to the clinical trial team (CTT) lead for a pediatric efficacy/safety/PK study in Sugammadex (timeline management, risk identification and mitigation, issue resolution); facilitated and collaborated with key internal/external stakeholders; accountable for managing study specific partners and/or vendors.

Design and conduct of clinical studies in Anesthesia & Critical Care, including: protocol development, protocol level planning, operational feasibility, aggregate safety reporting, clinical study reports, investigator brochures, manuscripts, regulatory agency update reports, investigator outreach and advisory board development, safety and medical monitoring, and training planning & execution.I also served as subject matter expert in Neuromuscular Transmission Monitoring & the TOF-Watch SX device for MRL in the US.

Phase IIb Efficacy and Population PK study in Migraine ( MK-1602 / ubrogepant ) Phase IIIb/V study in Anesthesia / Neuromuscular BlockadePhase IIIb Emerging Markets / Local Registration study (South Korea) in Anesthesia / Neuromuscular Blockade

Senior Clinical Trial Associate in Anesthesia & Analgesia, US Phase IIIb of SugammadexTrainer / SME / Medical Device Support for the Anesthesia Franchise: TOF-Watch device (measures neuromuscular function)

Technical PM of Data Management CRO, Phase III CellCept in SLE (Systemic Lupus Erythematous)

Phase II, III CellCept in Myasthenia Gravis

Merck Research Labs - Financial data analysis